USA flag logo/image

An Official Website of the United States Government

Back

Company Information:

Company Name: ARONORA, LLC
City: PORTLAND
State: OR
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,455,351.00 5
SBIR Phase II $7,239,016.00 3

Award List:

Development of a Sequencing Batch Biofilm Reactor for Treatment of Pesticide Rinsewater

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: USDA
Principal Investigator: Dale Watson
Award Amount: $75,000.00
Abstract:
NON-TECHNICAL SUMMARY: Pesticide formulation and agricultural-chemical facilities generate a dilute troublesome pesticide rinsewater that is difficult to dispose of due to its low volume, highly variable flow and the presence of a mixture of pesticides, solvents and emulsifiers. The sequencing batch… More

Therapeutic thrombin analogs

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Erik I. Tucker
Award Amount: $457,672.00
Abstract:
DESCRIPTION (provided by applicant): Stroke and heart attack are the leading causes of mortality and grave morbidity. The goal of this Fast-Track STTR grant application is to enable preclinical investigation of WE-thrombin, a bioengineered protein C activa tor enzyme for the treatment of severe,… More

Therapeutic thrombin analogs

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Erik I. Tucker
Award Amount: $1,771,244.00
Abstract:
DESCRIPTION (provided by applicant): Stroke and heart attack are the leading causes of mortality and grave morbidity. The goal of this Fast-Track STTR grant application is to enable preclinical investigation of WE-thrombin, a bioengineered protein C activa tor enzyme for the treatment of severe,… More

Therapeutic factor XI blockade for sepsis

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Erik I. Tucker
Award Amount: $297,486.00
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR grant will support the initial commercial development of a single dose injectable biological product candidate, recombinant humanized anti-factor XI monoclonal therapeutic anticoagulant antibody, towar ds an investigational new drug (IND)… More

Factor XI inhibitor for thrombosis

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Erik I. Tucker – 503-522-3083
Award Amount: $309,528.00
Abstract:
DESCRIPTION (provided by applicant): Thrombotic cardiovascular diseases including venous thromboembolism, myocardial infarction, and ischemic stroke, remain leading causes of death and disability in the US. Although effective antithrombotic agents are available, these drugs inadvertently target… More

Therapeutic factor XI blockade for sepsis

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Erik I. Tucker – 503-522-3083
Award Amount: $2,957,729.00
Abstract:
DESCRIPTION (provided by applicant): This SBIR Phase II grant will support the commercial development of an injectable biological product candidate, a unique proprietary recombinant humanized anti-factor XI monoclonal antibody (AXIMAB), towards an investigational new drug (IND) application. The lead… More

Factor XI inhibitor for thrombosis

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Erik I. Tucker – 503-522-3083
Award Amount: $2,510,043.00
Abstract:
DESCRIPTION (provided by applicant): Thrombotic cardiovascular diseases including venous thromboembolism (VTE), deep vein thrombosis (DVT), myocardial infarction, and ischemic stroke, remain leading causes of death and disability in the U.S. Although effective antithrombotic agents are available,… More

Factor XI Inhibition for the Treatment of Ischemic Stroke

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Philberta Y. Leung – 202-321-4634
Award Amount: $315,665.00
Abstract:
DESCRIPTION (provided by applicant): One of the underlying causes of acute ischemic stroke (AIS) is the thrombotic-thromboembolic occlusion of cerebral blood vessels. Early use of tissue-type plasminogen activator (tPA, Activase(R)), currently the only FDA-approved treatment for AIS, can promote… More
Back